{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:45:47Z","timestamp":1787021147051,"version":"build-2736575974"},"reference-count":8,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncology Advances"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1200\/oa-25-00037","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:59:06Z","timestamp":1744905546000},"source":"Crossref","is-referenced-by-count":3,"title":["SWOG 2308: Randomized Phase III Study of Mosunetuzumab Versus Rituximab for Low\u2013Tumor Burden Follicular Lymphoma"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct06337318","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":true,"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Bellasea","sequence":"additional","affiliation":[{"name":"SWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3063-3670","authenticated-orcid":true,"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"SWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":true,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-2569","authenticated-orcid":true,"given":"Locke","family":"Bryan","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Statistics & Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3138"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70066-X"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002858"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02327"},{"key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2024-194604","article-title":"Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: Updated results from the phase II Morningsun study","volume":"144","author":"Burke JM","year":"2024","unstructured":"Burke JM, Flinn IW, Budde EL, et al: Fixed-duration subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: Updated results from the phase II Morningsun study. Blood 144:3008, 2024","journal-title":"Blood"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8651"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:59:09Z","timestamp":1744905549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1200\/OA-25-00037"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00037","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"article-number":"e2500037"}}